Two Sigma Advisers LP cut its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 55.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 261,400 shares of the company's stock after selling 330,600 shares during the quarter. Two Sigma Advisers LP owned about 0.28% of Scholar Rock worth $11,298,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in the stock. FMR LLC raised its position in Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares during the period. Price T Rowe Associates Inc. MD raised its position in Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock valued at $401,231,000 after purchasing an additional 629,315 shares during the period. Vanguard Group Inc. raised its position in Scholar Rock by 17.6% in the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares during the period. Marshall Wace LLP raised its position in Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after purchasing an additional 2,732,546 shares during the period. Finally, Bellevue Group AG raised its position in Scholar Rock by 16.2% in the fourth quarter. Bellevue Group AG now owns 2,510,690 shares of the company's stock valued at $108,512,000 after purchasing an additional 349,487 shares during the period. 91.08% of the stock is owned by hedge funds and other institutional investors.
Scholar Rock Stock Up 0.0%
Shares of NASDAQ SRRK traded up $0.01 during midday trading on Wednesday, reaching $30.48. 99,726 shares of the company's stock were exchanged, compared to its average volume of 1,266,094. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The stock has a market capitalization of $2.89 billion, a PE ratio of -12.97 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The business's fifty day moving average price is $30.63 and its two-hundred day moving average price is $36.00.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period last year, the business posted ($0.59) earnings per share. Analysts forecast that Scholar Rock Holding Co. will post -2.42 EPS for the current year.
Insider Buying and Selling
In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the transaction, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tracey Sacco sold 5,000 shares of Scholar Rock stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the transaction, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,355,552.50. The trade was a 6.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,798 shares of company stock worth $5,482,238. Corporate insiders own 13.30% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $42.67.
Read Our Latest Research Report on SRRK
Scholar Rock Company Profile
(
Free Report)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Further Reading
Before you consider Scholar Rock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.
While Scholar Rock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
